{
    "eid": "2-s2.0-85051829925",
    "title": "Implementation of hepatitis B vaccine in high-risk young adults with waning immunity",
    "cover-date": "2018-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Biochemistry, Genetics and Molecular Biology (all)",
            "@code": "1300",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Agricultural and Biological Sciences (all)",
            "@code": "1100",
            "@abbrev": "AGRI"
        },
        {
            "@_fa": "true",
            "$": "Multidisciplinary",
            "@code": "1000",
            "@abbrev": "MULT"
        }
    ],
    "keywords": [],
    "authors": [
        "Nawarat Posuwan",
        "Arnond Vorayingyong",
        "Vorapol Jaroonvanichkul",
        "Rujipat Wasitthankasem",
        "Nasamon Wanlapakorn",
        "Sompong Vongpunsawad",
        "Yong Poovorawan"
    ],
    "citedby-count": 15,
    "ref-count": 31,
    "ref-list": [
        "Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization",
        "The Immunogenicity and Reactogenicity of Combined Tetravalent Diphtheria, Tetanus, Pertussis, and Hepatitis B Vaccine in Infants",
        "Experience of combined tetravalent diphtheria, tetanus, whole-cell pertussis and hepatitis B vaccine in Thailand",
        "Comparative evaluation of a combined DTP-HB vaccine in the EPI in Chiangrai Province, Thailand",
        "Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination",
        "The success of a universal hepatitis b immunization program as part of thailand\u2019s epi after 22 years\u2019 implementation",
        "Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP)",
        "Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity",
        "Hepatitis B and the need for a booster dose",
        "Hepatitis B vaccination: A completed schedule enough to control HBV lifelong? Milan, Italy, 17\u201318 November 2011",
        "Lifelong protection against hepatitis B: The role of vaccine immu-nogenicity in immune memory",
        "Markers of protection in children and adolescents six to fourteen years after primary hepatitis B vaccination in real life: A pilot study",
        "Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers",
        "Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program",
        "Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose",
        "Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers",
        "Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers",
        "Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age",
        "Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18\u201320 years after neonatal immunization",
        "Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand",
        "Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region",
        "Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers",
        "Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: A 20-year follow-up study in Thailand",
        "Hepatitis B vaccine\u2014what to expect",
        "Hepatitis B virus infection",
        "A 9-year follow-up study of the immunoge-nicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates",
        "Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "National Science and Technology Development Agency",
        "Centre of Excellence in Plant Energy Biology, Australian Research Council"
    ]
}